These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9459147)

  • 1. The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554.
    Aboagye EO; Maxwell RJ; Horsman MR; Lewis AD; Workman P; Tracy M; Griffiths JR
    Br J Cancer; 1998; 77(1):65-70. PubMed ID: 9459147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.
    Aboagye EO; Kelson AB; Tracy M; Workman P
    Anticancer Drug Des; 1998 Sep; 13(6):703-30. PubMed ID: 9755726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia.
    Aboagye EO; Maxwell RJ; Kelson AB; Tracy M; Lewis AD; Graham MA; Horsman MR; Griffiths JR; Workman P
    Cancer Res; 1997 Aug; 57(15):3314-8. PubMed ID: 9242466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy.
    Seddon BM; Maxwell RJ; Honess DJ; Grimshaw R; Raynaud F; Tozer GM; Workman P
    Clin Cancer Res; 2002 Jul; 8(7):2323-35. PubMed ID: 12114437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between tumour oxygenation, bioenergetic status and radiobiological hypoxia in an experimental model.
    Nordsmark M; Grau C; Horsman MR; Jörgensen HS; Overgaard J
    Acta Oncol; 1995; 34(3):329-34. PubMed ID: 7779418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy.
    Lee CP; Payne GS; Oregioni A; Ruddle R; Tan S; Raynaud FI; Eaton D; Campbell MJ; Cross K; Halbert G; Tracy M; McNamara J; Seddon B; Leach MO; Workman P; Judson I
    Br J Cancer; 2009 Dec; 101(11):1860-8. PubMed ID: 19935799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS). Studies in the SCCVII/C3H murine model.
    Papadopoulou MV; Pouremad R; Bloomer WD; Wyrwicz A
    Anticancer Res; 2006; 26(5A):3259-63. PubMed ID: 17094438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperpolarized magnetic resonance spectroscopy for assessing tumor hypoxia.
    Iversen AB; Ringgaard S; Laustsen C; Stødkilde-Jørgensen H; Bentzen L; Busk M; Horsman MR
    Acta Oncol; 2015; 54(9):1393-8. PubMed ID: 26340044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of hypoxia and hyperoxia on nucleoside triphosphate/inorganic phosphate, pO2 and radiation response in an experimental tumour model.
    Nordsmark M; Maxwell RJ; Horsman MR; Bentzen SM; Overgaard J
    Br J Cancer; 1997; 76(11):1432-9. PubMed ID: 9400939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an in vivo 19F magnetic resonance method for measuring oxygen deficiency in tumors.
    Raleigh JA; Franko AJ; Kelly DA; Trimble LA; Allen PS
    Magn Reson Med; 1991 Dec; 22(2):451-66. PubMed ID: 1812379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue oxygen tension measurements in the Shionogi model of prostate cancer using 19F MRS and MRI.
    McNab JA; Yung AC; Kozlowski P
    MAGMA; 2004 Dec; 17(3-6):288-95. PubMed ID: 15605277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo.
    Maxwell RJ; Workman P; Griffiths JR
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):925-9. PubMed ID: 2703398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel fluorinated hypoxia-targeted compounds as Non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS).
    Papadopoulou MV; Ji M; Bloomer WD
    Anticancer Res; 2006; 26(5A):3253-8. PubMed ID: 17094437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volume and carbogen breathing.
    Bentzen L; Keiding S; Horsman MR; Grönroos T; Hansen SB; Overgaard J
    Acta Oncol; 2002; 41(3):304-12. PubMed ID: 12195751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation.
    Horsman MR; Khalil AA; Siemann DW; Grau C; Hill SA; Lynch EM; Chaplin DJ; Overgaard J
    Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):439-42. PubMed ID: 8005796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between radiobiological hypoxia and direct estimates of tumour oxygenation in a mouse tumour model.
    Horsman MR; Khalil AA; Nordsmark M; Grau C; Overgaard J
    Radiother Oncol; 1993 Jul; 28(1):69-71. PubMed ID: 8234872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous murine tumours.
    Horsman MR; Nordsmark M; Høyer M; Overgaard J
    Br J Cancer; 1995 Dec; 72(6):1474-8. PubMed ID: 8519662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy.
    Seddon BM; Payne GS; Simmons L; Ruddle R; Grimshaw R; Tan S; Turner A; Raynaud F; Halbert G; Leach MO; Judson I; Workman P
    Clin Cancer Res; 2003 Nov; 9(14):5101-12. PubMed ID: 14613987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current issues in the utility of 19F nuclear magnetic resonance methodologies for the assessment of tumour hypoxia.
    Robinson SP; Griffiths JR
    Philos Trans R Soc Lond B Biol Sci; 2004 Jun; 359(1446):987-96. PubMed ID: 15306411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe SR-4554.
    Aboagye EO; Lewis AD; Graham MA; Tracy M; Kelson AB; Ryan KJ; Workman P
    Anticancer Drug Des; 1996 Apr; 11(3):231-42. PubMed ID: 8663910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.